Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

9480	Companies
185558	Keywords
117947	Articles
99388	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 06/09/2025 at 22:20, 5 months 25 days ago

Jaguar Health discutera des résultats de l'essai de phase 3 lors d'une discussion virtuelle

Jaguar Health Essai De Phase 3 Cancer Du Sein Maladies Orphelines Réunion De La FDA
BRIEF

published on 06/09/2025 at 22:20, 5 months 25 days ago

Jaguar Health to Discuss Phase 3 Trial Results in Virtual Chat

Jaguar Health Phase 3 Trial Breast Cancer Orphan Diseases FDA Meeting
PRESS RELEASE

published on 06/09/2025 at 22:15, 5 months 25 days ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health, Inc. to discuss Phase 3 OnTarget trial results for metastatic breast cancer subgroup. Focus on orphan population and expanded access program. Virtual fireside chat with CEO Lisa Conte on June 10, 2025

Jaguar Health Phase 3 OnTarget Trial Virtual Fireside Chat Metastatic Breast Cancer Orphan Population
BRIEF

published on 06/09/2025 at 15:05, 5 months 26 days ago

Jaguar Health Discusses Crofelemer Pathway with FDA

Crofelemer FDA Approval Orphan Drug Designation Metastatic Breast Cancer Expanded Access Program
BRIEF

published on 06/09/2025 at 15:05, 5 months 26 days ago

Jaguar Health discute du protocole Crofelemer avec la FDA

Crofelemer Désignation De Médicament Orphelin Approbation De La FDA Cancer Du Sein Métastatique Programme D'accès Élargi
PRESS RELEASE

published on 06/09/2025 at 15:00, 5 months 26 days ago

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Jaguar Health's Napo Pharmaceuticals shares plans to seek approval for crofelemer in cancer therapy-related diarrhea for metastatic breast cancer patients. Key discussions with FDA highlighted in Type C Meeting

Napo Pharmaceuticals Crofelemer Jaguar Health Cancer Therapy Metastatic Breast Cancer
BRIEF

published on 06/06/2025 at 15:05, 5 months 29 days ago

Jaguar Health to Discuss Orphan Disease Efforts in Upcoming Fireside Chat

Napo Pharmaceuticals Crofelemer Jaguar Health Fireside Chat Orphan Disease
BRIEF

published on 06/06/2025 at 15:05, 5 months 29 days ago

Jaguar Health discutera de ses efforts en matière de maladies orphelines lors d'une prochaine discussion informelle.

Napo Pharmaceuticals Crofelemer Jaguar Health Discussion Au Coin Du Feu Maladie Orpheline
PRESS RELEASE

published on 06/06/2025 at 15:00, 5 months 29 days ago

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health's CEO Lisa Conte will participate in a virtual fireside chat on June 10, 2025 to discuss the company's orphan disease development programs

Pharmaceuticals Jaguar Health Lisa Conte Virtual Fireside Chat Orphan Disease Development
BRIEF

published on 05/21/2025 at 14:05, 6 months 15 days ago

Jaguar Health réalise une offre publique d'achat directe enregistrée de 1,5 million de dollars

Nasdaq Placement Privé Jaguar Health Actions Ordinaires Offre Directe

Accesswire

Published on 12/05/2025 at 21:45, 23 minutes ago

When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 38 minutes ago

The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 48 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 1 hour 8 minutes ago

The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 1 hour 43 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 3 hours 10 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 3 hours 42 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 3 hours 53 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 4 hours 17 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 4 hours 22 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 4 hours 50 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 4 hours 50 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 6 hours 57 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 6 hours 57 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 8 hours 10 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE